The infix preceding the -mab suffix denotes the animal origin of the antibodies. Although the original monoclonal antibodies were produced in mice (infix, -o-), these antibodies are recognized as foreign by human immune systems and may be rapidly cleared, provoke an allergic reaction, or both. Therefore, parts of the antibody may be replaced with human sequences. If the constant region is replaced with the human form, it is termed chimeric and the infix used is -xi-. Part of the variable regions may also be substituted, in which case it is termed humanized and the infix used is -zu-. Antibodies originating in humans use -u-.
The infix preceding the source of the antibodies refers to medicine’s target. Most of these consist of a consonant, vowel, then another consonant. For ease of pronunciation and to avoid awkwardness, the final consonant is dropped if the following infix begins with a consonant (such as -zu- or -xi-). Examples of these include -ci(r)- for the circulatory system and -tu(m)- for miscellaneous tumors (cancers).
Finally, the prefix carries no special meaning and should be unique for each medicine. A second word may be added if there is another substance attached or linked.
Prefix | Target | Source | Suffix | ||
---|---|---|---|---|---|
varies | -vi(r)- | viral | -u- | human | -mab |
-ba(c)- | bacterial | -o- | mouse | ||
-li(m)- | immune | -a- | rat | ||
-le(s)- | infectious lesions | -e- | hamster | ||
-ci(r)- | cardiovascular | -i- | primate | ||
-co(l)- | colonic tumor | -xi- | chimeric | ||
-me(l)- | melanoma | -zu- | humanized | ||
-ma(r)- | mammary tumor | ||||
-go(t)- | testicular tumor | ||||
-go(v)- | ovarian tumor | ||||
-pr(o)- | prostate tumor | ||||
-tu(m)- | miscellaneous tumor |
Examples
Abciximab is a commonly used medication to prevent platelets from clumping together. It can be broken down into ab- + -ci(r)- + -xi- + -mab. Therefore, it is a chimeric monoclonal antibody used on the cardiovascular system.
Another example is the breast cancer medication trastuzumab, which can be broken down into tras- + -tu(m)- + -zu- + -mab. Therefore, it is a humanized monoclonal antibody used against a tumor.
References
- AMA (USAN) Monoclonal antibodies. American Medical Association (2006-02-14). Retrieved on 2006-07-09.
- Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances (PDF) pp. 27–28. World Health Organization (1997). Retrieved on 2006-07-09.